NCT03039101View on ClinicalTrials.gov

Leukotriene Antagonism in Recruitment of CD49d Expressing Neutrophils in Atopic Subjects

NACompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 6, 2017

Primary Completion Date

July 16, 2018

Study Completion Date

July 16, 2018

Conditions
Nasal Allergy
Interventions
PROCEDURE

Nasal lavage

determine frequency of CD49d expressing neutrophils in the nasal lavage by flow cytometry

PROCEDURE

Nasal allergen challenge

A small amount of allergen extract will be applied to one naris.

PROCEDURE

Epicutaneous skin testing

Skin testing (prick) to determine allergies.

PROCEDURE

Peripheral blood

Peripheral blood draw

DRUG

Montelukast 10Mg Tablet

one pill orally, daily, for 1 week

DRUG

Placebo Oral Tablet

one pill orally, daily, for 1 week

Trial Locations (1)

43205

Nationwide Children's Hospital, Columbus

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Mitchell Grayson

OTHER

NCT03039101 - Leukotriene Antagonism in Recruitment of CD49d Expressing Neutrophils in Atopic Subjects | Biotech Hunter | Biotech Hunter